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Abstract
Background
In Africa, the magnitude of dengue virus (DENV) transmission is largely unknown. In Burkina
Faso, several outbreaks have been reported and data are often based on findings from out-
break investigations.
Methods
To better understand dengue epidemiology and clinical characteristics in Burkina Faso, a
fever surveillance study was conducted among patients aged 1–55 years, who presented
with non-malarial febrile illness at five primary healthcare facilities in Ouagadougou, Burkina
Faso from December 2014 to February 2017, encompassing a 3-month dengue outbreak in
September-November 2016. Acute and convalescent blood samples were collected within
an interval of 10–21 days between visits. Acute samples were tested with dengue rapid
diagnostic tests (RDT) and a selected subset with RT-PCR, and all acute/convalescent
samples with IgM/IgG ELISA.
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Results
Among 2929 non-malarial febrile patients, 740 (25%) were dengue–positive based on RT-
PCR and/or IgM/IgG ELISA; 428 out of 777 patients (55%) and 312 out of 2152 (14%) were
dengue-positive during outbreak and non-outbreak periods, respectively. There were 11%
(316/2929) and 4% (129/2929) patients showing positive for NS1 and IgM, on the RDT,
respectively. DENV 2 predominated during the outbreak, whereas DENV 3 predominated
before the outbreak. Only 25% of dengue-positive cases were clinically diagnosed with sus-
pected dengue. The odds of requiring observation for�3 days (versus routine outpatient
care) were 11 times higher among dengue-positive cases than non-dengue cases. In
adjusted analyses, dengue-positivity was associated with rash and retro-orbital pain (OR =
2.6 and 7.4, respectively) during the outbreak and with rash and nausea/vomiting (OR = 1.5
and 1.4, respectively) during the non-outbreak period.
Conclusion
Dengue virus is an important pathogen in Burkina Faso, accounting for a substantial propor-
tion of non-malarial fevers both during and outside outbreak, but is only infrequently sus-
pected by clinicians. Additional longitudinal data would help to further define characteristics
of dengue for improved case detection and surveillance.
Author summary
There is not much evidence on dengue in Africa, relative to the Asia-Pacific and Latin
American regions. To estimate the proportion of dengue among patients with fever, and
to identify clinical features of dengue during outbreak and non-outbreak periods, we stud-
ied 2929 patients with non-malarial fever, aged 1–55 years, who attended five primary
healthcare centers in Ouagadougou, Burkina Faso. Patients were tested with a rapid test
for dengue, and further tests were carried out on paired blood samples taken 10–21 days
apart. Overall, a quarter of non-malarial febrile episodes identified between December
2014 and February 2017 were dengue-positive. Dengue-positive cases were 11 times more
likely than non-dengue cases to require observation for�3 days. During the study period
in 2016, there was a dengue outbreak where more than half of non-malarial febrile
patients were identified to be dengue-positive. DENV 2 was the main serotype in circula-
tion during the outbreak, whereas DENV 3 was the main serotype before the outbreak.
Rash and retro-orbital pain were more frequently found among dengue-positive cases,
compared to non-dengue cases, during the outbreak. During the non-outbreak period,
rash and nausea/vomiting were more likely in dengue-positive versus non-dengue cases.
There was a low level of clinical suspicion of dengue even during the 2016 outbreak.
Therefore, a broader use of rapid diagnostic tests and more epidemiologic data would
help to improve dengue case detection and surveillance in Burkina Faso.
Introduction
Dengue Fever (DF) is a mosquito-borne disease caused by four related but antigenically distinct
dengue viruses (DENVs, serotypes 1–4). Approximately 50 to 100 million cases of DF and
500,000 severe dengue cases requiring hospitalization reportedly occur annually worldwide [1–3].
Dengue outbreak in 2016 in Burkina Faso
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The Aedes mosquito vectors of DENV are widely distributed in Africa, and dengue cases
have been reported in 34 African countries [4–6]. However, data are limited to retrospective
testing of existing samples or outbreak investigations from a few countries [5, 7–9]. Several
studies have identified DENV as a common cause of febrile illness in Africa, but there is a con-
tinued challenge to distinguish dengue from other causes of febrile illness given limited diag-
nostic capabilities [10–12].
In Burkina Faso, several outbreaks have been reported since 1925 [5, 13, 14], including an
outbreak declared in November 2013 by the Burkina Faso Ministry of Health (MoH) [11, 15].
Between 5 August and 12 November 2016, the Burkina Faso MoH conducted an outbreak
investigation as part of emergency response in collaboration with World Health Organization
(WHO) and 1266 suspected dengue cases were identified by the MoH, with 1061 cases positive
by dengue rapid diagnostic test (RDT), and 15 deaths from all 12 districts of Ouagadougou
[16, 17]. Most recently, an even larger outbreak occurred in September 2017, with 9029 sus-
pected dengue cases, 5773 dengue RDT-positive cases, and 18 deaths throughout the country
[18]. These repeated outbreaks suggest a considerable dengue burden in Burkina Faso.
Most African countries lack mandatory reporting or national surveillance systems for den-
gue [19]. Burkina Faso added dengue to its routine national surveillance system for diseases
with epidemic-potential in 2016. Also, the MoH conducts outbreak investigations at several
sentinel health centers [11].
To better understand the dengue problem in Burkina Faso, a passive facility-based fever
surveillance study was conducted in Ouagadougou, from 2014–2017. During the study period,
the 2016 dengue outbreak occurred, allowing for characterization of dengue epidemiology and
comparison of clinical features during and outside the outbreak.
Methods
Study area and population
The study area was selected based on the existence of previous outbreaks and case reports, past
seroprevalence and modelling studies, as well as the availability of research infrastructure [4,
20, 21]. Ouagadougou is the capital city of Burkina Faso in West Africa with most of its popu-
lation residing in urban settings [22]. In March-May, temperatures may reach 43˚C, and it is
followed by the rainy season in May-September. Health services in Ouagadougou are provided
by three university hospitals, five district hospitals, and 60 primary healthcare centers (CSPS,
Centres de Sante´ et de Promotion Sociale), as well as private clinics [23].
The current study was implemented in five CSPSs (Pazani, CSPS22, CSPS25, Juvenat Fille,
Zongo), serving a catchment population of 110,000 residents (Fig 1). The population in Ouagadou-
gou is stable with an annual transmigration rate of 4.1% and>80% with home ownership [24].
Study design
Investigational methods can be found in previous publication [20]. The passive facility-based
fever surveillance study enrolled outpatients and observation patients (for�3 days), as previ-
ously described [20], between December 2014 and February 2017 (27 months). Patients pre-
senting with fever (body temperature� 37.5º C) or history of (self-reported) fever for�7 days
were tested for malaria using RDT (SD BIOLINE Malaria kit, Standard Diagnostics, Yongin-
Si, Korea) as part of routine practice. Patients were eligible for study enrolment if they were
malaria RDT-negative without localizing signs (i.e., no localized infection or known/con-
firmed non-dengue etiology), aged 1–55 years, resident of the catchment area covered by the
study CSPSs, and provided informed consent, plus assent for individuals aged 8–17 years.
Dengue outbreak in 2016 in Burkina Faso
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Malaria RDT-negative patients were tested using dengue RDTs. During the enrollment
visit, an acute blood sample (7–10 ml) was collected (Fig 2). Then, a study physician/nurse
conducted interviews and physical exams, and a surveillance case report form was completed
capturing symptom history, medical history, treatment and laboratory results [20]. A conva-
lescent blood sample was collected at the facility between 10–14 days after the initial visit, or if
not possible within this timeframe, the patient was followed up at home within 21 days.
Laboratory testing algorithm
Laboratory testing algorithm has been described in previous publication [20]. As described
previously [20], acute samples were tested at enrollment at the CSPS using a commercial RDT
Fig 1. A map of the study area in Ouagadougou, Burkina Faso. The map shows the approximate location of the selected facilities of 5 CSPSs (Pazani,
CSPS22, CSPS25, Juvenat Fille, Zongo), serving a catchment population of 110,000 residents of Ouagadougou, Burkina Faso [20].
https://doi.org/10.1371/journal.pntd.0007882.g001
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for dengue nonstructural protein 1 (NS1) and Immunoglobulin type M and type G (IgM/IgG)
(Dengue Duo, Standard Diagnostics, Yongin-Si, Korea). The acute and convalescent samples
were transported in 4ºC ice boxes to Virology laboratory of CHU YO (University Hospital
Center Yalgado Oue´draogo, in French: “Centre Hospitalier Universtaire Yalgado Oue´draogo”)
where blood samples were centrifuged and separated into cryotubes in 0.5–1 ml serum aliquots
under sterile conditions, labeled and stored at -70˚C freezer. Subsequently, they were brought
and tested in the Centre Muraz laboratory using dengue IgM/IgG Enzyme-Linked Immuno-
sorbent Assay (ELISA) (SD Dengue IgM & IgG Capture ELISA, Standard Diagnostics, Yon-
gin-Si, Korea). Furthermore, as described in previous publication [20], Reverse Transcriptase-
Polymerase Chain Reaction (RT-PCR) for laboratory confirmation of dengue infection and
serotyping [25] was performed at the International Vaccine Institute (IVI), on acute sera from
patients who had: (i) NS1 or IgM positive by RDT in the acute sample; and/or (ii) sero-conver-
sion between acute and convalescent samples by IgM and IgG capture ELISA. RT-PCR was
Fig 2. A chart of patient flow in passive fever surveillance. A chart of patient flow in passive fever surveillance- The
chart shows the study flow when a febrile patient presents at the CSPS from screening, enrollment, and lab testing.
https://doi.org/10.1371/journal.pntd.0007882.g002
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also performed on a limited number of randomly selected acute sera that were: (iii) sero-posi-
tive in both acute and convalescent samples by IgM and IgG capture ELISA; or (iv) IgG posi-
tive by RDT in the acute sample; or (v) negative by RDT and ELISA on all samples.
Dengue infection status was categorized based on interpretation of laboratory results, fol-
lowing WHO diagnostic criteria [26]. Sero-conversion by dengue IgM and/or IgG between
acute and convalescent samples and/or virus detection by RT-PCR in the acute sample were
considered to be laboratory-confirmed dengue. Positive IgM by ELISA in a single acute sample
or paired acute/convalescent samples, or NS1 and/or IgM positive by RDT were considered as
probable dengue [26]. Confirmed and probable dengue cases were combined into a dengue-
positive group for this analysis. Patients with negative RT-PCR and negative paired acute/con-
valescent IgM ELISA were classified as non-dengue.
Statistical analysis
There were 2 components in the analysis. First, a descriptive summary of clinical and labora-
tory characteristics is presented for dengue-positive and non-dengue cases. Elevated body tem-
perature, as a dichotomous variable, was defined as body temperature�38.5˚C, the 75th
percentile of the body temperature measured at enrollment. Clinical diagnosis (i.e., made by
clinician prior to laboratory confirmation) was grouped as suspected dengue, undifferentiated
fever, and other illness. Our surveillance covered the entire outbreak from September to
November 2016. Cases were also designated as outbreak or non-outbreak depending on date
of occurrence, with outbreak cases considered as those occurring between September and
November 2016, defined to be consistent with the outbreak period declared by Burkina Faso
MoH/WHO [16, 17]. Yellow fever (YF) vaccination history was dichotomized between those
who reported having been vaccinated versus those who did not remember or reported no vac-
cination. Categorical pair-wise comparisons were made across dengue infection status using
χ2 or Fisher’s exact tests with significance level of 0.05 [27]. Continuous variables were com-
pared using Student’s t-test or ANOVA [28].
Secondly, based on our a priori hypothesis that clinical presentation associated with den-
gue-positivity would be different between the outbreak and non-outbreak periods, logistic
regression was used to build a multivariable model of clinical indicators associated with den-
gue-positive vs. non-dengue cases, to separately fit the outbreak and non-outbreak periods.
The models contained age and gender as a priori confounders, possibly associated with expo-
sure to Aedes vectors, and with some clinical features [29]. A backward stepwise process was
used to select a final multivariable model for each outbreak status, with a significance level of
0.2 for entry and 0.1 for retention. Further variables investigated included: demographic and
clinical variables such as YF vaccination history, requirement for observation, fever duration
prior to enrollment, temperature at presentation, and clinical signs/symptoms. Some signs and
symptoms were used only in the descriptive and univariate analyses, due to data sparsity. Clin-
ical diagnosis of suspected dengue was considered to be closely related to the outcome of den-
gue-positivity and was not included.
Finally, a single set of variables was obtained as the union of the sets of variables from
regression modelling in the outbreak and non-outbreak periods. Variables found to be signifi-
cant in only one period were applied to both periods, producing a single list of variables. These
variables were fitted to both outbreak and non-outbreak periods to give comparable results
between them.
As part of sensitivity analysis, a descriptive summary of clinical and laboratory charac-
teristics using three categories for dengue infection status—confirmed, probable, and
non-dengue—is presented in supplementary S2 Table. Between dengue-confirmed and
Dengue outbreak in 2016 in Burkina Faso
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non-dengue groups, univariate logistic analyses were conducted for during and outside
the outbreak (S3 and S4 tables). All analyses were performed using SAS version 9.4 (SAS
Institute, Cary, North Carolina).
Ethical considerations
The study protocol received ethical approvals from the Institutional Review Boards (IRBs) of
IVI (No. 2014–008), the London School of Hygiene and Tropical Medicine (Reference num-
ber: 17096), the National Ethical Committee for Health Research of Burkina Faso, and the Eth-
ics Committee of the Centre Hospitalier de l’Universite´ de Montre´al (CRCHUM) at
University of Montreal.
A written informed consent from (ICF) was obtained from each participant. For those aged
between 8 and 17 years, an assent form was obtained, plus informed consent from at least one
parent or legal guardian.
Results
Analysis was performed on 2929 out of 3012 enrolled patients with complete clinical and labo-
ratory data; 83 withdrew consent or had incomplete laboratory data to determine dengue
infection status (Fig 3). Although similar in terms of age, gender, requirement for observation,
and days of illness before enrollment, these 83 patients were significantly different from the
analysis sample in terms of residential neighborhood—the majority from Zongo (40%) and
Pazani (28%)—and being mostly from non-outbreak periods (87%). In terms of missing data,
only the patients requiring observation had information on the complete blood count (CBC)
test and the results from CBC were not included in the analysis.
Clinical characteristics between dengue-positive and non-dengue cases
Table 1 describes demographic and clinical characteristics of dengue-positive vs. non-dengue
cases. Of 2929 analyzed patients, 2189 (74.7%) were non-dengue and 740 (25.3%) were den-
gue-positive. Of the 740 dengue-positive patients, 540 (73.0%) were laboratory-confirmed and
200 (27.0%) were probable dengue. Of the dengue-positive cases, 42% (n = 317) were con-
firmed by RT-PCR and the remainder by paired ELISA (Fig 3). A small peak in dengue-posi-
tive cases was observed in October-December 2015. A much larger peak occurred in August-
December 2016 (Fig 4). Both peaks occurred at the end or after the May-September rainy sea-
son. Of 777 fever cases from the outbreak, 55.1% (n = 428) were dengue-positive, with DENV2
predominating [181/258 (70%) of samples confirmed by RT-PCR] (Fig 4). Of 2152 non-out-
break fever cases, 14.5% (n = 312) were dengue-positive, mostly with DENV3 [28/43 (65%) of
samples confirmed by RT-PCR] and a few DENV1 [5/43 (12%) of samples confirmed by
RT-PCR].
Overall, dengue-positive cases were older than non-dengue cases (Table 1). Among den-
gue-positive cases, those after the 2016 outbreak were younger than those before or during the
outbreak (about 75%<30 years old, compared to before and during the outbreak with about
50%<30 years) (Fig 5); the age difference before, during and after the outbreak was statisti-
cally significant (ANOVA, p-value < .001). Differences in terms of presenting signs and symp-
toms are presented in Table 2.
There were 180 patients requiring observation at the CSPS. Patients later determined to be
dengue-positive were more likely, on presentation, to require observation: 18% of dengue-pos-
itive cases versus 2% of non-dengue cases (Table 1). A small but significant difference was
observed in average time between fever onset and enrollment for dengue-positive versus non-
dengue cases (2.9 days vs. 2.6 days, p< .001). Likewise, the entire duration of fever illness on
Dengue outbreak in 2016 in Burkina Faso
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average was significantly longer for dengue-positive cases (mean 4.7 versus 4.0 days, among
the 2926 patients with such data, p< .001). Dengue-positive cases were half as likely to self-
report that they had been vaccinated for YF (17%, versus 38% for non-dengue cases, p< .001).
Of 2929 available RDT results, 11% (316/2929) and 4% (129/2929) were positive for NS1
and IgM, on the RDT kit, respectively (Fig 1). There were 38 patients [28 (74%) during the out-
break and 10 (26%) during the non-outbreak periods] with positive results for both NS1 and
IgM on the RDT. During the outbreak period, 86% (271/316) were NS-1 positive and 40% (52/
129) were IgM positive (28 showing positive on both NS1 and IgM).
Only 25% of dengue-positive cases were clinically diagnosed with suspected dengue, prior
to lab-confirmation, and more than 90% of non-dengue cases were clinically diagnosed with
undifferentiated fever. During the outbreak, 31.3% (131/428) of dengue-positive cases were
diagnosed with suspected dengue, while 17.0% (53/312) were diagnosed with suspected den-
gue during non-outbreak periods.
Fig 3. A chart of patient flow in passive fever surveillance. The diagram shows how we reached the study population
and the test results from collected samples, within the surveillance.
https://doi.org/10.1371/journal.pntd.0007882.g003
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Table 1. Demographic and clinical characteristics of dengue-positive and non-dengue cases in the facility-based fever surveillance established in Ouagadougou,
Burkina Faso, between December 2014 and February 2017.
Characteristics Dengue-positive
(n = 740)
Non-dengue
(n = 2189)
Total
(n = 2929)
p-value
Age group (years) < .001
1–4 37 (5.0) 275 (12.6) 312 (10.7)
5–9 43 (5.8) 149 (6.8) 192 (6.6)
10–14 45 (6.1) 129 (5.9) 174 (5.9)
15–19 85 (11.5) 231 (10.6) 316 (10.8)
20–24 110 (14.9) 366 (16.7) 476 (16.3)
25–29 134 (18.1) 375 (17.1) 509 (17.4)
30–34 94 (12.7) 269 (12.3) 363 (12.4)
35–39 71 (9.6) 155 (7.1) 226 (7.7)
40–44 57 (7.7) 111 (5.1) 168 (5.7)
45–49 33 (4.5) 67 (3.1) 100 (3.4)
50–55 31 (4.2) 62 (2.8) 93 (3.2)
Female 465 (62.8) 1563 (71.4) 2028 (69.2) < .001
CSPS < .001
Pazani 113 (15.3) 400 (18.3) 513 (17.5)
Zongo 91 (12.3) 592 (27.0) 683 (23.3)
CSPS22 65 (8.8) 240 (11.0) 305 (10.4)
CSPS25 266 (36.0) 502 (22.9) 768 (26.2)
Juvenat Fille 205 (27.7) 446 (20.4) 651 (22.2)
Under observation�3 days/OPD 135 (18.2)/605 (81.8) 45 (2.1)/2144 (97.9) 180 (6.2)/2749 (93.9) < .001
Mean days, fever duration prior to visit (SD) 2.92 (1.21) 2.61 (1.22) 2.69 (1.23) < .001
Fever duration prior to visit < .001
1–2 days 301 (40.7) 1153 (52.7) 1454 (49.6)
3 days 238 (32.2) 634 (29.0) 872 (29.8)
4–7 days 201 (27.2) 400 (18.4) 603 (20.6)
Mean temperature at enrollment (SD) 38.29 (0.77) 38.03 (0.78) 38.09 (0.78) < .001
Temperature at enrollment < .001
Below 38.5˚c 478 (64.6) 1681 (76.8) 2159 (73.7)
� 38.5˚c 262 (35.4) 508 (23.2) 770 (26.3)
Mean days, fever duration, entire illness (SD) 4.72 (2.52) 4.04 (2.46) 4.21 (2.49) < .001
Prev. dengue infection (self-report) 14 (1.9) 2 (0.1) 16 (0.6) < .001
YF vaccination (self-report) < .001
Received 122 (16.5) 824 (37.6) 946 (32.3)
Not received 618 (83.5) 1365 (62.4) 1983 (67.7)
Clinical diagnosis
Suspected dengue 187 (25.3) 12 (0.6) 199 (6.8) < .001
Undifferentiated fever 529 (71.5) 1987 (90.8) 2516 (85.9)
Other illness 24 (3.2) 190 (8.7) 214 (7.3)
URI (% of other illness) 5 (20.8) 27 (14.2) 32 (15.0)
Bronchitis 4 (16.7) 30 (15.8) 34 (15.9)
Pneumonia 6 (25.0) 21 (11.1) 27 (12.6)
Viral syndrome 3 (12.5) 11 (5.8) 14 (6.5)
Diarrheal illness 2 (8.3) 28 (14.7) 30 (14.0)
Influenza 1 (4.2) 4 (2.1) 5 (2.3)
Others 3 (12.5) 69 (36.3) 72 (33.6)
https://doi.org/10.1371/journal.pntd.0007882.t001
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Clinical features associated with dengue during and outside the 2016
outbreak
Over the outbreak period, of the 740 dengue-positive patients, 357 patients (48%) were labora-
tory-confirmed. Of these dengue-confirmed cases, 258 (72%) were confirmed by RT-PCR; 55
(15%) by both IgM and IgG seroconversion; and 44 (12%) by IgM or IgG seroconversion on
paired ELISA. Over the non-outbreak period, of the 740 dengue-positive patients, 183 (25%)
patients were laboratory-confirmed. Of these dengue-confirmed cases, 59 (32%) were con-
firmed by RT-PCR; 10 (5%) by both IgM and IgG seroconversion; and 114 (62%) by IgM or
IgG seroconversion.
Demographic and clinical associations with dengue-positivity are shown in Table 3 for the
outbreak and in Table 4 for non-outbreak periods. During the outbreak, independently associ-
ated symptoms were: rash, retro-orbital pain, cough, headache, nausea/vomiting, and loss of
appetite. During non-outbreak periods, retro-orbital pain, headache, nausea/vomiting, and
constipation were independently associated. In addition to the symptoms, the multivariable
model selected requirement for observation and lack of YF vaccination to be associated with
dengue-positivity in both outbreak and non-outbreak periods. Age in non-outbreak periods
and, gender, elevated temperature at enrollment, and fever duration prior to enrollment in the
outbreak period were also selected. Age and gender were a priori confounders and were signif-
icantly associated with dengue-positivity. Enrolled CSPS may be a proxy for otherwise any
unexplained variation across centers, but was not selected for either of the outbreak or non-
Fig 4. Monthly distribution of febrile enrollees, dengue-positive and non-dengue cases & monthly distribution of
dengue serotypes� in PCR-positive cases. The figure has two parts: the upper part shows monthly distribution of
dengue-positive and non-dengue cases among the enrolled patients; and the lower part shows distribution of serotypes
identified (numbers shown in the bars) by month. �number of identified serotypes shown in the bars.
https://doi.org/10.1371/journal.pntd.0007882.g004
Dengue outbreak in 2016 in Burkina Faso
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007882 December 6, 2019 10 / 21
outbreak periods. In the absence of observation of variation with respect to dengue-positivity,
it was not entered in the models.
Table 5 shows the final set of variables. During both outbreak and non-outbreak periods,
dengue-positive patients had increased odds of presenting with rash [outbreak: 2.6 (95%
CI = 1.5–4.6); non-outbreak: 1.5 (95%CI = 1.0–2.4)] and retro-orbital pain [outbreak: 7.4 (95%
CI = 3.7–14.7); non-outbreak: 1.4 (95%CI = 1.01–1.8)].
Discussion
Recent reports of dengue outbreaks in Burkina Faso suggest substantial DENV transmission
in this region. However, existing evidence on epidemiological characterization of dengue in
Burkina Faso was limited in scope prior to this study. The current study collected population-
based epidemiologic data in Ouagadougou during a 27-month period from 2014–2017, includ-
ing all three months of the 2016 dengue outbreak. Our data demonstrated that dengue infec-
tion is an important cause of febrile illnesses, accounting for one-quarter of non-malarial
febrile illness in patients seeking care at CSPSs in the study. This proportion was very high
(55%) during the outbreak itself, but even outside the outbreak, a considerable proportion
Fig 5. Age distribution of dengue-positive cases before, during, and after the 2016 outbreak. The figure shows age
distribution of dengue-positive cases, compared to non-dengue cases, before, during, and after the 2016 outbreak.
https://doi.org/10.1371/journal.pntd.0007882.g005
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(15%) of non-malarial febrile episodes was dengue-positive. Since then, Ouagadougou has
experienced another, larger, dengue outbreak in 2017 [16, 18]. Recent outbreaks and the cur-
rent study indicate that DENV transmission is likely to be underestimated and underdiag-
nosed in Burkina Faso [16, 18].
Nonetheless, Burkina Faso is one of the countries in West Africa with better defined dengue
virus transmission and burden. Several other countries with some existing data are Nigeria,
Senegal, Ghana, and Sierra Leone. In Nigeria, presence of antibodies to DENV 2 was docu-
mented in 45% of 1816 human samples [30]. In Senegal, there were reported outbreaks of
DENV 3 in 2009 with 196 individuals affected and 5 cases of dengue haemorragic fever (DHF)
[31]. In Ghana, 3.2% among 218 children were found to show dengue IgM in 2014 [32]. In
Sierra Leone, presence of antibody to all four serotypes of dengue virus was documented,
based on neutralization test results on the samples from patients with fever of unknown origin
[33]. While these reports suggest dengue presence in several West African countries, some
with even high rates of infections, there is continued lack of data on dengue epidemiology in
the region and highlighted need for improved surveillance system.
Differences between outbreak and non-outbreak periods
The predominant DENV serotype identified from RT-PCR-positive outbreak cases in the
study was DENV2 (Fig 4). This was consistent to the results of MoH/WHO investigation of
the 2016 outbreak where DENV2 was the predominant serotype [16, 17]. DENV2 was also the
dominant serotype detected in outbreaks in Burkina Faso in 1982 and 1983–1986 [9, 34]. The
study found DENV3 to be predominant during the non-outbreak period preceding the 2016
Table 2. Signs and symptoms of dengue-positive and non-dengue cases in the facility-based fever surveillance established in Ouagadougou, Burkina Faso, between
December 2014 and February 2017.
Presence of signs and symptoms Dengue-positive
(n = 740)
Non-dengue
(n = 2189)
Total
(n = 2929)
p-value
Rash 95 (12.8) 163 (7.5) 258 (8.8) < .001
Fatigue 603 (81.5) 1526 (69.7) 2129 (72.7) < .001
Headache 708 (95.7) 1899 (86.8) 2607 (89.0) < .001
Retro-orbital pain 131 (17.7) 107 (4.9) 238 (8.1) < .001
Neck pain 13 (1.8) 47 (2.2) 60 (2.1) 0.517
Ear pain 2 (0.3) 10 (0.5) 12 (0.4) 0.741
Nasal congestion 20 (2.7) 105 (4.8) 125 (4.3) 0.015
Rhinorrhea 30 (4.1) 132 (6.0) 162 (5.5) 0.042
Sore Throat 11 (1.5) 64 (2.9) 75 (2.6) 0.032
Cough 91 (12.3) 354 (16.2) 445 (15.2) 0.011
Sputum production 4 (0.5) 30 (1.4) 34 (1.2) 0.075
Nausea & vomiting 270 (36.5) 635 (29.0) 905 (30.9) < .001
Diarrhea 23 (3.1) 128 (5.9) 151 (5.2) 0.004
Constipation 12 (1.6) 85 (3.9) 97 (3.3) 0.003
Abdominal pain 271 (36.6) 639 (29.2) 910 (31.1) < .001
Nose bleeding 7 (1.0) 10 (0.5) 17 (0.6) 0.130
Gum bleeding 5 (0.7) 2 (0.1) 7 (0.2) 0.013
Loss of appetite 331 (44.7) 739 (33.8) 1070 (36.5) < .001
Capillary refill >2 sec 8 (1.1) 19 (0.9) 27 (0.9) 0.600
Myalgia 319 (43.1) 560 (25.6) 879 (30.0) < .001
Arthralgia 426 (57.6) 953 (43.5) 1379 (47.1) < .001
https://doi.org/10.1371/journal.pntd.0007882.t002
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outbreak. DENV3 was the dominant serotype in the 2013 outbreak in Burkina Faso [35]. A
change in predominant DENV serotype may have fueled the outbreak in 2016. Although the
current study did not determine DENV strain, DENV2 strains reported from ill French travel-
ers returning from Burkina Faso in November 2016 were nearly identical to a DENV2 strain
detected in Burkina Faso in 1983 [36]. This suggests that the 2016 outbreak may have been due
to an endemic strain of DENV2 circulating in Burkina Faso for 30 years, perhaps maintained
Table 3. Univariate logistic analyses showing significant indicators and their odds ratios of dengue-positivity during the outbreak period, from the facility-based
fever surveillance established in Ouagadougou, Burkina Faso, between December 2014 and February 2017.
Characteristics During outbreak (n = 777)
Total N N (%) dengue-positive
(n = 428)
N (%)
Non- dengue
(n = 349)
Univariate analysis
Dengue-positive vs. non-dengue
OR 95% Confidence Interval (CI) p-Value
Age group (years) 0.195
1–14 129 63 (48.8) 66 (51.2) Ref -
15–24 213 121 (56.8) 92 (43.2) 1.38 0.89–2.14
25–34 242 128 (52.9) 114 (47.1) 1.18 0.77–1.80
35–55 193 116 (60.1) 77 (39.9) 1.58 1.01–2.47
Gender� 0.004
Male 293 181 (61.8) 112 (38.2) Ref -
Female 484 247 (51.0) 237 (49.0) 0.65 0.48–0.87
Under observation�� (ref. OPD) 128 110 (85.9) 18 (14.1) 6.36 3.77–10.71 < .001
Fever duration prior to visit� 0.007
1–2 days 330 168 (50.9) 162 (49.1) Ref -
3 days 244 129 (52.9) 115 (47.1) 1.08 0.78–1.51
4–7 days 203 131 (64.5) 72 (35.5) 1.75 1.23–2.51
Temperature at enrollment� 0.009
Below 38.5˚c 468 240 (51.3) 228 (48.7) Ref -
� 38.5˚c 309 188 (60.8) 121 (39.2) 1.48 1.10–1.98
No YF vaccination†� (ref. received vaccination) 630 363 (57.6) 267 (42.4) 1.72 1.19–2.46 0.004
Presence of signs and symptoms (ref. absence)
Rash� 84 60 (71.4) 24 (28.6) 2.21 1.34–3.63 0.002
Fatigue� 620 353 (56.9) 267 (43.1) 1.45 1.02–2.05 0.040
Retro-orbital pain�� 104 92 (88.5) 12 (11.5) 7.69 4.14–14.30 < .001
Headache� 749 420 (56.1) 329 (43.9) 3.19 1.39–7.33 0.006
Nasal congestion� 21 5 (23.8) 16 (76.2) 0.25 0.09–0.68 0.007
Rhinorrhea� 28 7 (25.0) 21 (75.0) 0.26 0.11–0.62 0.002
Cough�� 81 28 (34.6) 53 (65.4) 0.39 0.24–0.63 < .001
Nausea & vomiting 285 154 (54.0) 131 (46.0) 0.94 0.70–1.25 0.655
Diarrhea 21 8 (38.1) 13 (61.9) 0.49 0.20–1.20 0.120
Abdominal pain 263 153 (58.2) 110 (41.8) 1.21 0.90–1.63 0.216
Loss of appetite 383 217 (56.7) 166 (43.3) 1.13 0.85–1.50 0.385
Myalgia�� 366 227 (62.0) 139 (38.0) 1.71 1.28–2.27 < .001
Arthralgia 521 295 (56.6) 226 (43.4) 1.21 0.89–1.63 0.219
Statistical significance of the frequencies
�p-value<0.05
��p-value < .001
†based on self-report
https://doi.org/10.1371/journal.pntd.0007882.t003
Dengue outbreak in 2016 in Burkina Faso
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007882 December 6, 2019 13 / 21
partly through a sylvatic cycle [36]. More detailed phylogenetic analysis of DENVs from the
current study is planned.
Only a quarter of dengue-positive cases received a clinical diagnosis of suspected dengue in
this study, with this proportion being only slightly higher during the 2016 outbreak (31% of
dengue cases were suspected clinically) compared to outside the outbreak (17%). In the routine
care system, clinicians in the CSPS refer to a guideline issued by the Burkina Faso MoH [37],
primarily based on the 2009 WHO dengue guidelines. The dengue RDTs were made available
Table 4. Univariate logistic analyses showing significant indicators and their odds ratios of dengue-positivity during non-outbreak periods, from the facility-based
fever surveillance established in Ouagadougou, Burkina Faso, between December 2014 and February 2017.
Characteristics During non-outbreak (n = 2152)
Total N N (%) dengue-positive
(n = 312)
N (%)
Non- dengue
(n = 1840)
Univariate analysis
Dengue-positive vs. non-dengue
OR 95% CI p-Value
Age group (years)� 0.003
1–14 549 62 (11.3) 487 (88.7) Ref -
15–24 579 74 (12.8) 505 (87.2) 1.15 0.80–1.65
25–34 630 100 (15.9) 530 (84.1) 1.48 1.06–2.08
35–55 394 76 (19.3) 318 (80.7) 1.88 1.31–2.70
Gender
Male 608 94 (15.5) 514 (84.5) Ref -
Female 1544 218 (14.1) 1326 (85.9) 0.90 0.69–1.17 0.426
Under observation�� (ref. OPD) 52 25 (48.1) 27 (51.9) 5.85 3.35–10.22 < .001
Fever duration prior to visit� 0.001
1–2 days 1124 133 (11.8) 991 (88.2) Ref -
3 days 628 109 (17.4) 519 (82.6) 1.57 1.19–2.06
4–7 days 400 70 (17.5) 330 (82.5) 1.58 1.15–2.17
Temperature at enrollment 0.285
Below 38.5˚c 1691 238 (14.1) 1453 (85.9) Ref -
� 38.5˚c 461 74 (16.1) 387 (84.0) 1.17 0.88–1.55
No YF vaccination†�� (ref. received vaccination) 1353 225 (18.9) 1098 (81.2) 3.02 2.24–4.09 < .001
Presence of signs and symptoms (ref. absence)
Rash� 174 35 (20.1) 139 (79.9) 1.55 1.05–2.29 0.029
Fatigue�� 1509 250 (16.6) 1259 (83.4) 1.86 1.39–2.50 < .001
Retro-orbital pain�� 134 39 (29.1) 95 (70.9) 2.62 1.77–3.89 < .001
Headache�� 1858 288 (15.5) 1570 (84.5) 2.06 1.33–3.19 0.001
Nasal congestion 104 15 (14.4) 89 (85.6) 0.99 0.57–1.74 0.982
Rhinorrhea 134 23 (17.2) 111 (82.8) 1.24 0.78–1.98 0.366
Cough 364 63 (17.3) 301 (82.7) 1.29 0.96–1.75 0.096
Nausea & vomiting�� 620 116 (18.7) 504 (81.3) 1.57 1.22–2.02 < .001
Diarrhea 130 15 (11.5) 115 (88.5) 0.76 0.44–1.32 0.325
Abdominal pain� 647 118 (18.2) 529 (81.8) 1.51 1.17–1.94 0.001
Loss of appetite 687 114 (16.6) 573 (83.4) 1.27 0.99–1.64 0.059
Myalgia� 513 92 (29.5) 421 (82.1) 1.41 1.08–1.84 0.012
Arthralgia 858 131 (15.3) 727 (84.7) 1.11 0.87–1.41 0.409
Statistical significance of the frequencies
�p-value<0.05
��p-value < .001
†based on self-report
https://doi.org/10.1371/journal.pntd.0007882.t004
Dengue outbreak in 2016 in Burkina Faso
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007882 December 6, 2019 14 / 21
at the CSPSs in the study, but the results of dengue RDT might not have contributed to the
clinical assessment, if the results were not made available in time (dependent on patient vol-
ume and clinician availability). Dengue RDTs are typically unavailable for routine use in
Africa; and many non-malaria febrile etiologies, including dengue, are likely to be under-diag-
nosed [12, 38]. Clinicians in Burkina Faso may need to consider dengue more frequently as a
clinical diagnosis, with or without point-of-care assays.
Our multivariable analysis showed differing patterns of signs and symptoms associated
with dengue-positivity during the outbreak period compared to non-outbreak periods. Rash
was associated with dengue-positivity during both outbreak and non-outbreak periods. Rash is
a common sign for dengue and listed in dengue classification in both 1997 and 2009 WHO
dengue guidelines [3, 39, 40]. However, retro-orbital pain showed increased odds of dengue-
positivity only during the outbreak. Retro-orbital pain, also listed in the 2009 WHO case defi-
nition, is another common sign associated with dengue-positivity [3, 39, 40]. Also, it was sug-
gested that ocular symptoms, including retro-orbital pain, in dengue patients may possibly
indicate thrombocytopenic state with increased likelihood of hemorrhage [41]. In our data,
Table 5. Multivariate logistic analysis showing significant indicators and their odds ratios of dengue-positivity by outbreak or non-outbreak periods, in the facility-
based fever surveillance established in Ouagadougou, Burkina Faso, between December 2014 and February 2017.
Characteristics Multivariate analysis
During outbreak� (n = 777)
ref. non-dengue (n = 349)
During non-outbreak (n = 2152)
ref. non-dengue (n = 1840)
Dengue-positive
(n = 428)
p-Value Dengue-positive
(n = 312)
p-Value
aOR 95% CI aOR 95% CI
Female (ref. Male) 0.63 0.45–0.89 0.008 0.98 0.73–1.30 0.869
Age (years) 0.612 0.041
1–14 Ref Ref
15–24 1.23 0.73–2.06 1.18 0.80–1.75
25–34 0.99 0.59–1.64 1.45 0.98–2.14
35–55 1.24 0.73–2.09 1.74 1.16–2.62
Under observation�3 days (ref. OPD) 6.01 3.33–10.84 < .001 4.32 2.33–8.02 < .001
No YF vaccination� (ref. received vaccination) 1.73 1.12–2.68 0.013 2.42 1.76–3.32 < .001
Temperature at enrollment 0.015 0.752
Below 38.5˚c Ref Ref
� 38.5˚c 1.54 1.09–2.17 1.05 0.77–1.44
Fever duration prior to visit 0.081 0.087
1–2 days Ref Ref
3 days 0.93 0.62–1.41 1.40 1.04–1.89
4–7 days 1.53 0.97–2.43 1.25 0.87–1.80
Presence of signs and symptoms (ref. absence)
Rash 2.59 1.46–4.59 0.001 1.54 1.00–2.37 0.049
Retro-orbital pain 7.37 3.69–14.71 < .001 1.42 0.90–2.25 0.134
Nausea & vomiting 0.75 0.52–1.08 0.117 1.36 1.01–1.82 0.042
Cough 0.36 0.21–0.63 < .001 1.21 0.87–1.69 0.248
Loss of appetite 0.46 0.30–0.71 < .001 0.93 0.69–1.27 0.659
Headache 2.28 0.93–5.62 0.072 1.43 0.90–2.29 0.130
Constipation 1.08 0.23–4.97 0.926 0.52 0.24–1.10 0,087
�based on self-report
aOR = adjusted odds ratio
https://doi.org/10.1371/journal.pntd.0007882.t005
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dengue-positive patients with retro-orbital pain were 5.8 times (95% C.I: 3.5–9.6, p< .001)
more likely to require observation than dengue-positive patients without retro-orbital pain
during the outbreak. During non-outbreak, it also showed a similar pattern with statistical sig-
nificance, but with a wide confidence interval. Therefore, further information is needed for
validation. While hemorrhagic signs were not commonly reported in our data, requiring
observation may indicate severity of dengue illness and retro-orbital pain being associated
with dengue-positive cases in the outbreak may indicate likely severity of dengue illness during
the outbreak.
Our data showed a high proportion of individuals 15–40 years of age among dengue-posi-
tive cases in the outbreak period (a mean age of 26.8 years in dengue-positive patients). This
was also found in the outbreak investigation by the Burkina Faso MoH with WHO where 70%
of affected people were 25 years and older, with a mean age of 30 years [16]. It suggests that
those in the labor force may be impacted, leading to significant economic and social burden
[42]. Adjusted for age and gender, our model found higher odds that dengue-positive cases
required observation, compared to non-dengue, during both outbreak (6.0 times) and non-
outbreak (4.3 times) periods. Given the substantial proportion of dengue-positive cases among
non-malarial febrile illnesses, this suggests that dengue may account for greater utilization of
healthcare resources in CSPSs than other etiologies, during both outbreak and non-outbreak
periods. As in many other parts of Africa, these primary healthcare centers have limited
resources, such as beds [43], and could be especially overextended during outbreaks. Since the
study only enrolled patients at CSPSs, the burden on the healthcare system due to dengue
inpatients is unclear.
Self-report of not having received YF vaccination was associated with increased odds of
dengue-positivity. A priori, one might have hypothesized cross-protection. However, the
opposite phenomenon of a predisposition of YF vaccinated individuals to DHF has been sug-
gested, with a possible explanation of cross-reactivity between antibodies from YF vaccination
and dengue virus. [44]. Without much data on association of YF vaccination and dengue infec-
tion, self-reporting may be unreliable due to recall bias, and the study could not confirm YF
vaccination using patient records.
Study limitations
DENV transmission can vary substantially over time and space. Hence, the generalizability of
the current study is limited by enrollment from the five selected CSPSs in the capital during
the 27-month study period. We would have missed those community residents with relevant
symptoms seeking care elsewhere than study centers, including private providers. In addition,
patients with severe illness would have not been enrolled since they would likely have sought
care directly at inpatient facilities; and subclinical and mild DENV infections would also not
have been detected.
The study surveillance excluded patients with malaria RDT positive results, localizing signs
or known/confirmed diagnosis with other diseases, possibly omitting co-infections of dengue
with another pathogen. In particular, given the prevalence of malaria in this region, dengue
and malaria co-infection were not included in this study and may require further investigation.
Nevertheless, the available information on co-infections suggests they are uncommon [9, 45–
48].
Performance of malaria RDTs, in terms of sensitivity, would depend on local conditions,
especially the level of malaria transmission shown to be variable from reported incidence in
Ouagadougou [49, 50]. There could have been misclassification among non-malarial patients
(i.e. false negative results on malaria RDT included in the study being differently classified
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between dengue-positive and non-dengue groups). Also, this could vary by the level of dengue
transmission (i.e. during and outside of the outbreak), leading to differential misclassification.
Our findings were based on outpatients and patients requiring observation, and clinical
characteristics may be different for hospitalized patients and individuals with subclinical infec-
tions. Also, such findings may depend on other co-circulating pathogens endemic in the area,
however our study did not confirm etiologies of non-dengue cases. Therefore, further infor-
mation on the etiologies of non-dengue febrile cases may be needed to verify which signs are
useful in distinguish non-dengue from dengue illnesses [51].
In our analysis, laboratory-confirmed and probable dengue cases were combined into the
dengue-positive group. There may be some limitations with probable dengue being not as cer-
tain as lab-confirmed dengue. However, we performed analysis using 3 categories of dengue
infection status (lab-confirmed-; probable-; and non-dengue) as part of sensitivity analysis and
this yielded similar results (see S2–S4 Tables).
Conclusion
Dengue is an important cause of non-malarial fever in Burkina Faso, both during and outside
of outbreaks, despite being infrequently suspected by clinicians. Despite the many possible eti-
ologies of febrile illness in this region, limited surveillance and diagnostic capacity will con-
tinue to pose challenges to dengue prevention and control. Additional longitudinal studies to
better characterize dengue epidemiology and clinical presentation, including in inpatients and
for subclinical/mild cases, along with encouraged use of dengue RDTs, would help to inform
strategies to approach dengue countermeasures in this region.
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